Subtopic Deep Dive
Phosphorylation by Pim Kinases
Research Guide
What is Phosphorylation by Pim Kinases?
Phosphorylation by Pim kinases refers to the serine/threonine phosphorylation of substrates like BAD and 4E-BP1 by PIM1, PIM2, and PIM3 kinases, promoting cell survival and protein translation in cancer cells.
Pim kinases, identified through proviral integrations in murine lymphomas, phosphorylate pro-apoptotic proteins to inhibit cell death (Brault et al., 2010, 363 citations). PIM2 constitutively inhibits apoptosis when overexpressed in hematopoietic cells deprived of growth factors (Fox et al., 2003, 329 citations). These kinases cooperate with Akt in oncogenic signaling, with over 20 studies mapping their substrates in hematologic and solid tumors.
Why It Matters
Pim kinase phosphorylation sustains cancer cell survival by inactivating BAD and enhancing cap-dependent translation via 4E-BP1, offering targets for inhibitors in leukemia and lymphoma therapies (Amaravadi, 2005, 401 citations; Brault et al., 2010). STAT3 activation downstream of Pim signaling drives AML blast survival, where small-molecule inhibitors induce apoptosis (Redell et al., 2011, 259 citations). Precision inhibitors targeting Pim-Akt crosstalk improve outcomes in relapsed hematologic malignancies, as elevated PIM1/PIM2 levels correlate with poor prognosis (Brault et al., 2010).
Key Research Challenges
Identifying Pim Substrates
Mapping precise phosphorylation sites on substrates like BAD remains incomplete due to kinase redundancy with Akt (Amaravadi, 2005). Few studies use phosphoproteomics to distinguish Pim-specific events from overlapping signals (Brault et al., 2010). Validating functional impacts in vivo is limited by murine models.
Developing Selective Inhibitors
Pim kinases lack regulatory domains, complicating ATP-competitive inhibitor design without off-target effects on related kinases (Brault et al., 2010). Clinical translation faces resistance from JAK/STAT co-activation (Amaravadi, 2005). Trials show limited efficacy in solid tumors due to pathway crosstalk (Zhong et al., 2021).
Overcoming Tumor Heterogeneity
PIM1/PIM2 expression varies across hematologic vs. solid cancers, hindering pan-Pim therapies (Brault et al., 2010). STAT3-independent activation in AML blasts evades single-agent inhibition (Redell et al., 2011). Patient stratification by phosphoproteome profiles is underdeveloped.
Essential Papers
Targeting PI3K in cancer: mechanisms and advances in clinical trials
Jing Yang, Ji Nie, Xuelei Ma et al. · 2019 · Molecular Cancer · 1.5K citations
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Lei Zhong, Yueshan Li, Liang Xiong et al. · 2021 · Signal Transduction and Targeted Therapy · 1.5K citations
Abstract Due to the advantages in efficacy and safety compared with traditional chemotherapy drugs, targeted therapeutic drugs have become mainstream cancer treatments. Since the first tyrosine kin...
A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers
James R. Bischoff · 1998 · The EMBO Journal · 1.2K citations
How ERK1/2 activation controls cell proliferation and cell death: Is subcellular localization the answer?
Yohannes A. Mebratu, Yohannes Tesfaigzi · 2009 · Cell Cycle · 937 citations
Extracellular signal-regulated protein kinases 1 and 2 (ERK1/2) are members of the mitogen-activated protein kinase super family that can mediate cell proliferation and apoptosis. The Ras-Raf-MEK-E...
The survival kinases Akt and Pim as potential pharmacological targets
Ravi K. Amaravadi · 2005 · Journal of Clinical Investigation · 401 citations
The Akt and Pim kinases are cytoplasmic serine/threonine kinases that control programmed cell death by phosphorylating substrates that regulate both apoptosis and cellular metabolism. The PI3K-depe...
PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers
L. Brault, Christelle Gasser, Franz Bracher et al. · 2010 · Haematologica · 363 citations
The identification as cooperating targets of Proviral Integrations of Moloney virus in murine lymphomas suggested early on that PIM serine/threonine kinases play an important role in cancer biology...
The serine/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor
Casey Fox, Peter S. Hammerman, Ryan M. Cinalli et al. · 2003 · Genes & Development · 329 citations
Growth factor withdrawal results in the termination of factor-dependent transcription. One transcript that declines rapidly following growth factor deprivation of hematopoietic cells is the serine/...
Reading Guide
Foundational Papers
Start with Amaravadi (2005) for Pim-Akt pharmacology overview (401 citations); Fox et al. (2003) for Pim2 mechanism (329 citations); Brault et al. (2010) for pathogenesis across cancers (363 citations).
Recent Advances
Redell et al. (2011) on STAT3-Pim in AML (259 citations); Zhong et al. (2021) on targeted therapy challenges (1499 citations).
Core Methods
Phosphoproteomics for substrate ID; kinase assays with PIM inhibitors; overexpression in growth factor-deprived cells; JAK/STAT co-inhibition screens.
How PapersFlow Helps You Research Phosphorylation by Pim Kinases
Discover & Search
Research Agent uses searchPapers('Pim kinase substrates phosphorylation cancer') to retrieve Brault et al. (2010), then citationGraph to map 363 citing papers on Pim inhibitors, and findSimilarPapers to uncover overlooked BAD phosphorylation studies.
Analyze & Verify
Analysis Agent applies readPaperContent on Fox et al. (2003) to extract Pim2 apoptotic inhibition mechanisms, verifyResponse with CoVe to cross-check claims against Amaravadi (2005), and runPythonAnalysis for statistical verification of phosphosite motifs using NumPy/pandas on extracted data; GRADE grading scores evidence strength for therapeutic targeting.
Synthesize & Write
Synthesis Agent detects gaps in Pim-STAT3 crosstalk via contradiction flagging across Redell et al. (2011) and Brault et al. (2010), while Writing Agent uses latexEditText for substrate network revisions, latexSyncCitations to integrate 10+ references, latexCompile for figure-ready drafts, and exportMermaid for kinase-substrate diagrams.
Use Cases
"Analyze Pim2 phosphorylation motifs from Fox et al. 2003 and compute consensus sequences."
Research Agent → searchPapers → Analysis Agent → readPaperContent(Fox et al., 2003) → runPythonAnalysis(motif alignment with pandas/NumPy) → matplotlib motif plot and statistical p-values.
"Draft LaTeX review on Pim kinase inhibitors with citation-synced substrate table."
Synthesis Agent → gap detection → Writing Agent → latexEditText(intro) → latexSyncCitations(Brault 2010, Amaravadi 2005) → latexCompile → PDF with embedded kinase pathway figure.
"Find GitHub repos implementing Pim phosphoproteomics pipelines from recent papers."
Research Agent → exaSearch('Pim kinase phosphoproteomics code') → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → exportCsv of analysis scripts for BAD/4E-BP1 motifs.
Automated Workflows
Deep Research workflow conducts systematic review of 50+ Pim papers via searchPapers → citationGraph → DeepScan 7-step analysis with GRADE checkpoints on substrate validation (e.g., Fox et al., 2003). Theorizer generates hypotheses on Pim-Akt synthetic lethality from Brault et al. (2010) and Amaravadi (2005) via gap detection → contradiction flagging → exportMermaid networks. Chain-of-Verification/CoVe ensures hallucination-free summaries of phosphosite data.
Frequently Asked Questions
What defines phosphorylation by Pim kinases?
Pim kinases (PIM1-3) perform serine/threonine phosphorylation on substrates like BAD (inactivation) and 4E-BP1 (translation activation) to block apoptosis in cancer (Amaravadi, 2005).
What are key methods for studying Pim phosphorylation?
Phosphoproteomics distinguishes Pim motifs from Akt; overexpression models test apoptotic inhibition (Fox et al., 2003); inhibitor assays probe pathway dependence (Brault et al., 2010).
What are seminal papers on Pim kinases?
Amaravadi (2005, 401 citations) links Pim to Akt survival; Brault et al. (2010, 363 citations) reviews cancer roles; Fox et al. (2003, 329 citations) shows Pim2 as apoptotic inhibitor.
What open problems exist in Pim kinase research?
Selective inhibitor resistance via STAT3/JAK crosstalk (Redell et al., 2011); incomplete substrate maps beyond BAD/4E-BP1; heterogeneity in solid tumor expression (Brault et al., 2010).
Research Cancer Mechanisms and Therapy with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Phosphorylation by Pim Kinases with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Cancer Mechanisms and Therapy Research Guide